Karyopharm Therapeutics (KPTI) Expected to Announce Earnings on Thursday

Karyopharm Therapeutics (NASDAQ:KPTI) is projected to release its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Karyopharm Therapeutics to post earnings of ($2.26) per share and revenue of $33.16 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Karyopharm Therapeutics Trading Up 2.8%

Shares of NASDAQ KPTI traded up $0.17 during midday trading on Friday, reaching $6.26. The company had a trading volume of 520,560 shares, compared to its average volume of 406,867. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.38. The business’s 50-day simple moving average is $6.79 and its 200 day simple moving average is $6.12. The stock has a market cap of $114.62 million, a P/E ratio of -0.43 and a beta of 0.21.

Analyst Ratings Changes

Several analysts have weighed in on KPTI shares. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research note on Thursday. They set an “overweight” rating on the stock. Wall Street Zen raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. Royal Bank Of Canada cut their price target on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. HC Wainwright raised Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Monday, October 13th. Finally, The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a report on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors have recently bought and sold shares of the business. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $45,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth $56,000. Bridgeway Capital Management LLC purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth $163,000. ADAR1 Capital Management LLC acquired a new position in Karyopharm Therapeutics during the third quarter worth $164,000. Finally, Bank of America Corp DE lifted its holdings in Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares in the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.